HALOZYME THERAPEUTICS
European shares end lower on US Fed rate, Trump jittersEuropean shares fell on Friday, dragged down by disappointing earnings, concerns about the impact of U.S. President-elect Donald Trump's po...
Halozyme Therapeutics to acquire Antares Pharma in all-cash dealThe transaction, which values Antares at $960 million, demonstrates Halozyme's commitment to drug delivery.
- Load More